Drug
KHK7580
KHK7580 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Total Trials
7
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 7 completed trials
Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
14%(1 trials)
Phase Distribution
Ph phase_1
2
29%
Ph phase_2
1
14%
Ph phase_3
4
57%
Phase Distribution
2
Early Stage
1
Mid Stage
4
Late Stage
Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
4(57.1%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
7 of 7 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
7
all time
Status Distribution
Completed(7)
Detailed Status
Completed7
Development Timeline
Analytics
Development Status
Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (28.6%)
Phase 21 (14.3%)
Phase 34 (57.1%)
Trials by Status
completed7100%
Recent Activity
0 active trials
Showing 5 of 7
completedphase_3
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
NCT03822507
completedphase_3
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
NCT03280264
completedphase_3
Phase 3 Study of KHK7580
NCT02549404
completedphase_3
Phase 3 Study of KHK7580
NCT02549417
completedphase_2
Phase 3 Study of KHK7580
NCT02549391
Clinical Trials (7)
Showing 7 of 7 trials
NCT03822507Phase 3
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia
NCT03280264Phase 3
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
NCT02549404Phase 3
Phase 3 Study of KHK7580
NCT02549417Phase 3
Phase 3 Study of KHK7580
NCT02549391Phase 2
Phase 3 Study of KHK7580
NCT01935856Phase 1
Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
NCT02143271Phase 1
Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7